Why Is Belite Bio Stock Soaring Friday?
Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.
Stocks · News reference
Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.
Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.
StoneX analyst Michael Rindos initiates coverage on Lennar (NYSE:LEN) with a Hold rating.
Berkshire Hathaway CEO Greg Abel is making significant bets on a housing market recovery through multiple moves: acquiring homebuilder Taylor Morrison for $8.5 billion, increasing investment in Lennar by 30%, and buying shares of D.R. Horton. These moves, combined with existing holdings in Clayton Homes and Berkshire Hathaway Home Services, suggest Abel believes pent-up demand will emerge once mortgage rates decline, despite the currently frozen housing market.
Greg Abel, the new CEO of Berkshire Hathaway, is taking a more aggressive investment approach compared to his predecessor Warren Buffett. After 13 quarters of net stock selling under Buffett, Berkshire became a net buyer in Q2 2026, making significant purchases including $17 billion in Alphabet, along with positions in Delta Air Lines, Lennar, and Macy's. This marks a departure from Buffett's cautious stance that stocks are overvalued and behaving like a casino.